A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor

Authors :: Lichuang Men
Sreenivasa R Chandana
Yvette Cole
Yingjie Huang
Hengbang Wang
Nehal Lakhani
Kyriakos P. Papadopoulos
Timothy J. O'Rourke
Anthony W. Tolcher
Amita Patnaik
Qi Dong
Jiao Ji
Alex Amaya
Dajun Yang
Theresa Mays
Drew W. Rasco
Yifan Zhai
Brianne Kaiser
Source :: Journal of Clinical Oncology. 36:2594-2594
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 2594Background: We have developed a unique strategy to tactically reduce on-target platelet toxicity with APG-1252, a novel dual Bcl-2/Bcl-xL inhibitor, while maintaining strong in vivo antitumor a...

Subjects :: 0301 basic medicine
Cancer Research
business.industry
Phase i study
Bcl 2 bcl xl
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
In vivo
030220 oncology & carcinogenesis
Toxicity
Cancer research
Medicine
Platelet
In patient
Non small cell
business
Solid tumor

Full Text Access

Tools